Roche 'Man In Bosnia' Works To Improve Cancer Drug Access, Faces High Hurdles
Adnan Filipovic has 'a sense of mission' to get cancer sufferers in Bosnia and Herzegovina access to innovative drugs despite the huge obstacles in that war-damaged country.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.